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http://dx.doi.org/10The retinoblastoma gene (RB1) has been implicated as a tumor suppressor in multiple
myeloma (MM), yet its role remains unclear because in the majority of cases with 13q14 de-
letions, un-mutated RB1 remains expressed from the retained allele. To explore the role of Rb1
in MM, we examined the functional consequences of single- and double-copy Rb1 loss in
germinal center B cells, the cells of origin of MM. We generated mice without Rb1 function
in germinal center B cells by crossing Rb1Flox/Flox with C-g-1-Cre (Cg1) mice expressing
the Cre recombinase in class-switched B cells in a p107/ background to prevent p107
from compensating for Rb1 loss (Cg1-Rb1F/F-p107/). All mice developed normally, but
B cells with two copies of Rb1 deleted (Cg1-Rb1F/F-p107/) exhibited increased proliferation
and cell death compared with Cg1-Rb1+/+-p107L/L controls ex vivo. In vivo, Cg1-Rb1F/F-
p107/ mice had a lower percentage of splenic B220+ cells and reduced numbers of bone
marrow antigen-specific secreting cells compared with control mice. Our data indicate that
Rb1 loss induces both cell proliferation and death in germinal center B cells. Because no B-
cell malignancies developed after 1 year of observation, our data also suggest that Rb1 loss
is not sufficient to transform post-germinal center B cells and that additional, specific muta-
tions are likely required to cooperate with Rb1 loss to induce malignant transformation. Co-
pyright  2016 ISEH - International Society for Experimental Hematology. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Large deletions affecting chromosome 13 occur in 50% of
cases of multiple myeloma (MM) and are associated with
poor long-term survival [1]. The role of chromosome 13 de-
letions in MM has been the focus of intense study, but the
tumor suppressor gene(s) has not been conclusively identi-
fied [2]. The retinoblastoma (RB1) gene has been impli-ted equally to this work.
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.1016/j.exphem.2015.11.006cated as a candidate tumor suppressor at 13q14 in MM
[3]. Previously, we mapped chromosome 13 deletions in
MM and found a microdeletion in a t(4;14)-positive patient
that removed a single exon of RB1 critical for its function
[4]. High-resolution genetic studies, including single-
nucleotide polymorphism (SNP) array studies [5] and
whole-genome sequencing approaches [6,7], have also
found that RB1 is a recurrent deletion target in MM. Of
note though, retained RB1 alleles remain un-mutated and
expressed in the majority of cases of MM [8]. RB1 is the
gene that defined bi-allelic loss as the sine qua non of tumor
suppressor gene function [9], however, given the frequent
mono-allelic loss of RB1 and the central role of Cyclin D/
Rb pathway in MM, if RB1 is the target of chromosomeatology. Published by Elsevier Inc. This is an open access article under the
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allelically inactivated [10].
The function of Rb1 as a tumor suppressor has been well
studied, and genetically targeted mice have been invaluable
tools in dissecting the role of Rb1 in tumor development
[11,12]. Germline deletion of Rb1 is embryonic-lethal
with defects in neurogenesis and hematopoiesis [2,13,14].
Mice engineered with a conditional Rb1 allele develop pi-
tuitary tumors, illustrating the tumor-suppressor activity
of Rb1 [15,16]. However, mice with conditional loss of
Rb1 do not develop retinoblastoma tumors as was expected
from human genetic studies. In mice, two additional Rb
family members, p107 and p130, have redundant tumor
suppressor function [17–20], thus complicating the study
of the role of Rb1 in tumorigenesis. The p107 family mem-
ber is upregulated on Rb1 loss in the mouse retina, and
deletion of p107 is necessary before retinoblastoma tumors
develop [19].
To identify potential roles of Rb1 in MM pathogenesis,
we generated triple transgenic mice with conditional dele-
tion of Rb1 in germinal center (GC) B cells. We observed
increased proliferation in Rb1 null B cells stimulated to un-
dergo class-switch recombination (CSR). In vivo, mice with
Rb1 deleted in GC B cells had a smaller percentage of
splenic B220þ cells and fewer bone marrow antigen-
specific secreting cells (ASCs) compared with control
mice. Our data suggest that complete absence of Rb1 in
antigen-stimulated cells results in hyperproliferation
balanced by cell death.Figure 1. Generation of triple transgenic mice without Rb1 gene function in GC
subsets. mRNA microarray expression data (arbitrary units) of retinoblastoma fam
ulations from wild-type mice [21]. (B) Polymerase chain reaction (PCR) analysis
with IL-4 at the indicated time points (day 0 to day 7). b-actin was used as a lo
CD138þ cells of Rb1F/þ mouse after NP-CGG immunization by PCR. Lane 1:
mouse tail DNA, used as a negative control. (D) Recombination in a panel of c
mouse bone marrow B220þIgM–cells (early B cells), lane 2: mouse spleen B ce
loading control. (Color version of figure available online.)Methods
Detailed methods are described in the Supplementary Material
(online only, available at www.exphem.org).Results and discussion
We sought to generate strains of mice with Rb1 function
deleted from GC B cells. The Rb1 family members Rbl1
(p107) and Rbl2 (p130) compensate for Rb1 loss in some
cell types [19], so we examined the transcript expression of
all three retinoblastoma family genes at four stages of B-
cell development: naive B, GC B, plasma B, and memory
B cells [21]. We found that Rb1 and p107, but not p130,
were expressed in mature B-cell subsets including GC and
plasma cells (Fig. 1A). These data suggested that p107might
compensate for Rb1 loss in GC cells, so we generated triple
transgenic mice using the previously characterized condi-
tional Rb1Flox allele, Cg1-cre, which expresses cre recombi-
nase specifically in GCB cells [22], and a p107 null allele. In
this way, we established three strains of mice: Cg1-Rb1F/F-
p107/, Cg1-Rb1F/þ-p107/, and Cg1-Rb1þ/þ-p107/
(which will be referred to as Rb1F/F, Rb1F/þ, and Rb1þ/þ
for simplicity (Supplementary Figure E1, online only, avail-
able at www.exphem.org).
Recombination was successful at the Rb1 locus in
B cells from Rb1F/F mice stimulated to undergo CSR
ex vivo (Fig. 1B; Supplementary Figure E2, online only,
available at www.exphem.org). Recombination was also
detected in vivo in splenic GC cells (B220þGL7þIgG1þ)B cells. (A) Pattern of expression of Rb1 family members in mature B-cell
ily members Rb1, p107, and p130 in flow-sorted primary late B-cell pop-
of DNA isolated from Rb1F/F mouse spleen B cells after ex vivo stimulation
ading control. (C) Rb1 recombination in splenic B cells and bone marrow
mouse spleen B-cells, lane 2: mouse bone marrow CD138þ cells, lane 3:
ell types of Rb1F/F mouse after NP-CGG immunization by PCR. Lane 1:
lls, lane 3: bone marrow B220–Ly6Gþ cells (granulocytes). b-actin is the
163Z. He et al./ Experimental Hematology 2016;44:161–165and in post-GC plasma cells (B220–, CD138þ) of Rb1F/þ
mice (Fig. 1C). Small amounts of recombination were de-
tected in Rb1F/F bone marrow B cells, suggesting small
amounts of off-target cre expression in pre-GC B cells.
No recombination was detected in myeloid lineage cells
(Fig. 1D). To address the off-target effects observed in
the Rb1F/F mice, we mated Rb1F/F mice to AID-cre mice,
which drive cre expression in GC cells undergoing CSR.
These matings did not yield genotypes at expected mende-Figure 2. Hyperproliferation and cell death of B cells undergoing class-switch re
lated from Rb1þ/þ, Rb1F/þ, and Rb1F/F triple transgenic mice stimulated with IL
pulsed with BrdU, and the optical density (OD) at 450 nm was measured. The exp
ysis is shown. (B) Growth curves of splenic B cells derived from Rb1þ/þ, Rb1F/
were plated in triplicate on day 1. Cells were counted each day for 3 days using t
(trypan blue stained) on the right. The experiment was performed three separate
analysis of splenic CD138þB220 (plasma) cells of Rb1þ/þ and Rb1F/F triple tran
centage of bone marrow B220þ cells (n5 6 mice of each genotype) was analyzed
post-immunization (PI) with NP-CGG on splenocytes (left) and 8 weeks PI on
Rb1F/F mice. NP-CGG-specific antigen-secreting cells (ASCs) were quantitate
400,000 plated cells in duplicate is shown (n 5 6 mice per genotype). For the
are illustrated. For Rb1þ/þ, n 5 2, and for Rb1F/þ and Rb1F/F, n 5 4. For all ex
a two-tailed, unpaired t test. *p ! 0.05.lian frequencies, and we were unable to generate AID-Cre-
Rb1F/F-p107/ mice. This was likely due to embryonic
lethality, as AID is expressed in embryonic neuronal cells
[23], and Rb1 null mice are embryonic lethal because of
neuronal defects [2,13,14].
We anticipated cell cycle deregulation in GC B cells
with Rb1 deficiency, so we measured proliferation in naive
splenic B cells from our triple transgenic Rb1þ/þ, Rb1F/þ,
and Rb1F/F mice stimulated to undergo CSR ex vivo.combination. (A) Bromodeoxyuridine (BrdU) assay of splenic B cells iso-
-4 and LPS for 3 days. Equal numbers of cells from each genotype were
eriment was performed three times in quadruplicate; a representative anal-
þ, and Rb1F/F mice stimulated with IL-4 and LPS. Equal numbers of cells
rypan blue. Live cells (trypan blue excluded) are on the left, and dead cells
times in triplicate; a representative analysis is shown. (C) Flow cytometry
sgenic mice 2 weeks after NP-CGG immunization (left). The average per-
on separate days (right). (D) ELISA-SPOT assays were performed 2 weeks
whole bone marrow cells (BMCs) isolated from Rb1þ/þ, CG-Rb1F/þ, and
d by counting spots (Methods). For the splenocyte analysis, ASCs per
BMC analysis, percentages of ASCs per 460,000 plated cells in duplicate
periments, error bars are SEM. Statistical analyses were performed using
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cells compared with Rb1þ/þ controls assessed by both
BrdU incorporation (Fig. 2A) and cell growth assays
(Fig. 2B), although they did not proliferate past day 4 of
culture (not shown), suggesting the cells were not trans-
formed. We observed significantly more dead cells among
Rb1F/F B cells (Fig. 2B). Our observation that Rb1 defi-
ciency in GC B cells caused both increased proliferation
and cell death has been made in other cell types and is
consistent with Rb1’s well-known function as a cell cycle
checkpoint and apoptotic regulator [11].
To assess the effect of Rb1 deficiency on GC B cells
in vivo, we measured short-term GC splenic B-cell responses
following immunization. Mice were stimulated with NP-
CGG, and 2 weeks later, B-cell subsets were assessed by im-
munophenotyping using five-color flow cytometry. Despite
the ex vivo proliferation we observed, no significant differ-
ences were observed in immature B cells (IgMþ IgD), acti-
vated B cells (IgMþ IgDþ), follicular cells (IgMlow IgDþ),
GC B cells (B220þIgD–GL7þ, data not shown), or plasma
cells (B220–/low CD138þ) (Fig. 2C). We did observe a
decrease in the percentage of B220þ splenocytes isolated
from Rb1F/F mice compared with Rb1þ/þ control mice, sug-
gesting that Rb1 deficiency in early B cells may lead to
increased apoptosis, but no differences were observed in
the percentage of B220þCD138þ bone marrow plasma cells
across the three mouse strains (Fig. 2C).
We next measured antigen-specific plasma cell re-
sponses using NP-CGG ELISA-SPOT assays and spleno-
cytes from each of the three strains of mice.
Unexpectedly, the Rb1F/þ mice had an increase in splenic
NP-CGG-specific ASCs compared with Rb1þ/þ controls,
but the Rb1F/F mice did not. Following successful CSR in
GCs, B cells differentiate to plasma cells and home to the
bone marrow. To assess B-cell subsets at a later point
(8 weeks post-immunization [PI]), we measured B and
plasma cells in the bone marrow and spleen of the three
mouse strains by measuring percentages of each by flow cy-
tometry, as described above. We observed no significant
changes in any of the B-cell subsets we tested (data not
shown). To quantitate antigen-specific plasma cell re-
sponses, NP-CGG ELISA-SPOT assays were performed us-
ing bone marrow cells from each of the three strains of
mice. Rb1F/F mice had significantly fewer NP-CGG ASCs
compared with Rb1þ/þ mice, suggesting that loss of Rb1
in post-GC B cells may induce cell death.
Rb1F/þ and Rb1F/F mice developed normally and ap-
peared healthy. To screen these mice for malignancy, we as-
sessed an array of biomarkers when mice reached the age of
12 months after NP-CGG stimulation. Complete blood
counts (CBCs) revealed that, compared with Rb1F/þ and
Rb1þ/þ mice, Rb1F/F mice had slightly, but not significantly
increased white blood cell and lymphocyte counts
(Supplementary Figure E3, online only, available at www.
exphem.org). Serum protein electrophoresis (SPEP) anal-ysis revealed no significant M-proteins in any of the mice
(Supplementary Figure E4, online only, available at www.
exphem.org). X-Ray analysis was used to detect lytic
bone lesions, a hallmark of MM, but none were detected
(Supplementary Figure E5, online only, available at www.
exphem.org). No significant abnormalities were seen
in vivo, as determined with chemistry tests (serum creati-
nine, calcium, blood urea nitrogen, albumin, and total pro-
tein) and histopathologic analysis of organs (heart, liver,
lung, kidney, spleenddata not shown). These data suggest
that no MM or other B-cell malignancy developed in
Rb1F/þ or Rb1/– mice, within 12 months of follow-up.
Together our data indicate that Rb1 function is essential
for control of proliferation of GC B cells, but that loss of
this tumor suppressor is not sufficient to initiate malignant
transformation. Rather, B-cell numbers were decreased in
the absence of Rb1 (Fig. 2). The C-g-driven Cre expression
predicts recombination in GC B cells; however, we detected
‘‘off-target’’ recombination in bone marrow B cells (Fig. 1).
We also observed fewer NP-CGG-specific BM ASCs in
Rb1F/F mice. These results may be explained by the fact
that E2F factors activated by Rb1 loss induce apoptosis
through p53 in certain cell types [24]. This is consistent
with the observation that although haplo-insufficiency for
RB1 is common, complete loss of RB1 is rare in the absence
of other mutations to protect the cells from death.
Additional mutations are required to cooperate with Rb1
loss for malignant transformation of GC B cells. Our
finding that GC B cells haplo-insufficient for Rb1 hyper-
proliferate in response to antigen stimulation (Fig. 2) sug-
gests that malignant cells may optimize the Rb1 dose for
best proliferative advantage. This would provide an expla-
nation for the frequent mono-allelic RB1 loss and rare ho-
mozygous deletion in MM. Although RB1 is affected by
microdeletions and point mutations [4], large deletions
affecting 13q are far more common in MM. Large deletions
may facilitate MM growth and survival by simultaneously
reducing the expression of RB1 and another 13q gene or
genes. One such candidate is DIS3, a 30-to-50 RNA exonu-
clease recurrently mutated in MM and located at chromo-
some 13q22.1. Notably, DIS3 mutations detected in MM
reduce, but do not eliminate, DIS3 activity. Hypomorphic
DIS3 dysregulates the cell cycle through a mechanism
that increases centromeric RNA and modification of chro-
matin structures near centromeres (unpublished data). Our
mouse model will be a useful reagent for exploring the
role of cooperation between Rb1 loss and reduced Dis3 ac-
tivity and testing the role of Rb1 loss and MM-associated
gain-of-function oncogene mutations.
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To establish CG-Rb1F/F-p107/, CG-Rb1F/þ-p107/,
and CG-Rb1WT-p107/ mouse models that conditionally
delete Rb1 in spleen germinal center B cells, we generated
strains of mice by breeding Rb1Flox/Flox mice to the Rb
family member, p107/ mice. Rb1Flox/Flox-p107/
mice were bred to the germinal center-specific Cg1-Cre
mice that have the Cre recombinase knocked into the
endogenous Cg1 locus, which is expressed specifically dur-
ing B-cell class-switch recombination. Rb1F/F and p107/
mice were backcrossed 10 times to C57BL/6J. The p107/
mice retained their brown color-likely because the Agouti
genes are relatively close on chromosome 2 to p107. The
CG mice were on a C57BL/6J background when obtained.
Rb1 locus recombination was tested by polymerase chain
reaction, as previously described [2]. Products obtained
from Rb1LoxP alleles were 780 bp, and those from
Rb1WT alleles were 680 bp. Recombined alleles were
260 bp. At 6 weeks of age, all mice were immunized using
1 mg of (4-hydroxy-3-nitrophenyl) acetyl-conjugated
chicken g-globulin (NP-CGG; Biosearch Technologies),
which was mixed with Freund’s Adjuvant Complete or
Incomplete (Sigma-Aldrich) for primary or boosting immu-
nization in 100 mL to inject intraperitoneally to promote
germinal center B-cell activation and Rb1 conditional dele-
tion. All mice were maintained under specific pathogen-
free conditions and used according to institutional
guidelines.
Ex vivo class-switch recombination assay
Murine splenocytes were treated with red blood cell lysing
buffer (Sigma), and B cells were isolated using CD43 mag-
netic bead depletion (LD) columns (Miltenyi) Biotech with
an AutoMacs Pro separator according to the manufacturer’s
instructions. Splenic B cells were cultured with 20 ng/mL
interleukin (IL)-4 (R&D Systems, Minneapolis, MN) and
10 mg/mL lipopolysaccharide (LPS, Sigma-Aldrich) in B-
cell medium (RPMI-1640) with L-glutamine (Cellgro,
Manassas, VA), 1% HEPES, 1% penicillin/streptomycin/
amphotericin B, 10% fetal bovine serum (Hyclone, South
Logan, UT) for the indicated times.
Immunophenotyping by flow cytometry
Spleens and bone marrow were harvested from mice,
passed through 50-mm CellTrics filters (Partec) to generate
single-cell suspensions, and briefly treated with hypotonic
lysis buffer to remove red blood cells. Cells (10  106)
were then suspended in 0.5 mL staining buffer (phos-
phate-buffered saline, 0.5% bovine serum albumin, 0.05%
NaN3) and incubated with the following rat anti-mouse
monoclonal antibodies (all purchased from BD Biosciences
unless indicated otherwise) in the dark on ice for 30 min:
APC-Cy7 B220 (RA3-6B2), Brilliant Violet 421 CD138
(281-2), PE GL7 (GL7), FITC IgM (II/41), and PerCP-
Cy5.5 IgD (11-26c.2a, BioLegend). Cells were then washed
twice with staining buffer and resuspended in 0.5 mL; flow
cytometric analysis was performed on a FACScan (Becton
Dickinson), modified with additional lasers (Cytek Devel-
opment). A total of 1  106 events were collected. FlowJo
software (Tree Star) was used for data analysis.
Cell proliferation (BrdU and cell counting)
For bromodeoxyuridine (BrdU) assays, IL-4- and LPS-
treated B cells were cultured (as described above) for
3 days. On the third day, proliferation was tested by puls-
ing 25,000 cells of each genotype with BrdU for 2 hours
using an ELISA BrdU Kit (Cell Signaling) according to
the manufacturer’s instructions. For cell counting,
50,000 cells were plated for each genotype in triplicate
on day 1. Viable cells were counted using trypan blue
exclusion; cells that had taken up the dye were considered
dead and also counted. Cells were counted on a
hemocytometer.
ELISA-SPOT assays
MultiScreen nitrocellulose filter plates (EMD Millipore)
were coated with 50 mg/mL NP16-BSA (Biosearch Tech-
nologies) or BSA alone as a control and incubated over-
night at 4C. Splenocytes (2 weeks postimmunization) or
bone marrow cells (8 weeks postimmunization) were
seeded at decreasing doses in duplicate. Cells were cultured
in 100 mL overnight at 37C, 5% CO2. Wells were washed
with PBS with 0.5% Tween and stained with biotinylated
anti-mouse IgG. Plates were washed and next incubated
with streptavidin-conjugated horseradish peroxidase (BD
Pharmingen). Spots were developed using 3-amino-
9-ethyl-carbazole (Sigma). Once spots appeared, the reac-
tion was quenched by rinsing wells with water. Spots
were counted using an ImmunoSpot S6 Analyzer (CTL
Laboratories).
Complete blood count analysis
The complete blood count (CBC) was quantitated using the
HEMAVET 950 system (Drew Scientific, Dallas, TX).
Serum protein electrophoresis analysis
Serum samples were analyzed by serum protein electropho-
resis (SPEP) analysis on a Quickgel Chamber apparatus us-
ing precasted quickGels (Helena Laboratories) according to
the manufacturer’s instructions. Densitometric analysis of
the SPEP traces was performed using the clinically certified
Helena QuickScan 2000 workstation.
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Supplementary Figure E2. Ex vivo class switching of primary murine B cells and Cre-mediated recombination. Flow cytometery was used to measure the
IgG1 levels of CG-Rb1F/FP107/ splenic B cells after ex vivo class-switch recombination with medium only, LPS only, or LPS plus IL-4, at different time
points.
Supplementary Figure E1. Schematic of the three mouse strains.
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Supplementary Figure E3. Mouse blood cell counts 12 months after immunization. Total white blood cell counts (left) and lymphocyte counts (right) of
peripheral blood from the three mouse strains at the age of 12 months: CG-Rb1WT-p107/ (n 5 5), CG-Rb1F/þ-p107/ (n 5 6) and CG-Rb1F/F–p107/
(n 5 6) after NP-CGG immunization at the age of 6 weeks.
Supplementary Figure E4. Detection of M-protein bands by serum protein electrophoresis (SPEP). Top: SPEP gels for the three mouse strains. CG-
Rb1WTP107/ (lanes 1–5), CG-Rb1F/þP107/ (lanes 6–9), CG-Rb1F/FP107/ (lanes 10–15). NP 5 negative control, PC 5 positive control. The arrows
point to the g-globulin and albumin bands. Bottom: SPEP albumin/globulin (A/G) ratios for the different strains of mice (left) and SPEP gamma (g) fractions
(percentage of gamma fraction in total serum protein) for the three mouse strains.
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Supplementary Figure E5. Radiograph of mouse tails at the age of
12 months.
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